Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ$4.41
Market Cap
$307.1M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
249 of 924
Rank in Industry
142 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
PHAT Insider Trading Activity
PHAT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $180,332 | 2 | 17 |
Sells | $1,007,272 | 10 | 83 |
Related Transactions
| KARBE FRANK | director | 1 | $99,084 | 0 | $0 | $99,084 |
| Parikh Asit | director | 1 | $81,248 | 0 | $0 | $81,248 |
| Henderson Molly | CFO and CBO | 0 | $0 | 4 | $142,516 | $-142,516 |
| Nabulsi Azmi | Chief Operating Officer | 0 | $0 | 3 | $188,661 | $-188,661 |
| Curran Terrie | President and Chief Executive | 0 | $0 | 3 | $676,096 | $-676,096 |
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori …
Insider Activity of Phathom Pharmaceuticals, Inc.
Over the last 12 months, insiders at Phathom Pharmaceuticals, Inc. have bought $180,332 and sold $1.01M worth of Phathom Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Phathom Pharmaceuticals, Inc. have bought $2.44M and sold $23.22M worth of stock each year.
Highest buying activity among insiders over the last 12 months: KARBE FRANK (director) — $99,084. Parikh Asit (director) — $81,248.
The last purchase of 12,500 shares for transaction amount of $99,084 was made by KARBE FRANK (director) on 2024‑12‑13.
List of Insider Buy and Sell Transactions, Phathom Pharmaceuticals, Inc.
| 2025-01-21 | Sale | Curran Terrie | President and Chief Executive | 19,109 0.0281% | $6.59 | $125,884 | -15.91% | |
| 2025-01-21 | Sale | Nabulsi Azmi | Chief Operating Officer | 7,886 0.0116% | $6.59 | $51,957 | -15.91% | |
| 2025-01-21 | Sale | Henderson Molly | CFO and CBO | 6,583 0.0097% | $6.59 | $43,371 | -15.91% | |
| 2024-12-19 | Sale | Nabulsi Azmi | Chief Operating Officer | 1,118 0.0017% | $8.00 | $8,944 | -21.48% | |
| 2024-12-19 | Sale | Henderson Molly | CFO and CBO | 1,291 0.0019% | $8.00 | $10,328 | -21.48% | |
| 2024-12-13 | Parikh Asit | director | 10,000 0.0149% | $8.12 | $81,248 | -20.22% | ||
| 2024-12-13 | KARBE FRANK | director | 12,500 0.0182% | $7.93 | $99,084 | -20.22% | ||
| 2024-07-15 | Sale | Curran Terrie | President and Chief Executive | 33,848 0.0663% | $11.72 | $396,699 | -14.68% | |
| 2024-07-15 | Sale | Nabulsi Azmi | Chief Operating Officer | 10,901 0.0214% | $11.72 | $127,760 | -14.68% | |
| 2024-07-15 | Sale | Henderson Molly | CFO and CBO | 4,325 0.0085% | $11.72 | $50,689 | -14.68% | |
| 2024-04-08 | Sale | Henderson Molly | CFO and CBO | 3,435 0.0059% | $11.10 | $38,129 | -7.02% | |
| 2024-03-22 | Sale | Curran Terrie | President and Chief Executive | 16,851 0.0238% | $9.11 | $153,513 | -5.85% | |
| 2024-01-24 | Sale | TAKEDA PHARMACEUTICAL CO LTD | 10 percent owner | 3.7M 7.8033% | $8.10 | $30M | +55.14% | |
| 2024-01-19 | Sale | Henderson Molly | CFO and CBO | 6,307 0.0114% | $7.75 | $48,900 | +39.12% | |
| 2023-11-20 | Sale | Henderson Molly | CFO and CBO | 2,127 0.0037% | $7.24 | $15,403 | +40.42% | |
| 2023-11-08 | Parikh Asit | director | 2,500 0.0044% | $7.80 | $19,500 | +32.93% | ||
| 2023-11-07 | Parikh Asit | director | 4,000 0.0067% | $7.76 | $31,040 | +27.77% | ||
| 2023-11-06 | Parikh Asit | director | 1,000 0.0018% | $8.04 | $8,040 | +30.25% | ||
| 2023-11-01 | Sale | Henderson Molly | CFO and CBO | 12,492 0.0202% | $8.88 | $110,871 | +7.39% | |
| 2023-06-02 | Sale | Henderson Molly | CFO and CBO | 1,960 0.0045% | $11.41 | $22,368 | -13.46% |
Total: 116
*Gray background shows transactions not older than one year
Insider Historical Profitability
37.19%
| Curran Terrie | President and Chief Executive | 360465 0.5176% | $1.59M | 2 | 7 | +28.42% |
| Nabulsi Azmi | Chief Operating Officer | 233390 0.3352% | $1.03M | 2 | 16 | +23.07% |
| Henderson Molly | CFO and CBO | 93546 0.1343% | $412,537.86 | 1 | 12 | |
| Parikh Asit | director | 75500 0.1084% | $332,955.00 | 8 | 0 | +32.4% |
| KARBE FRANK | director | 57000 0.0819% | $251,370.00 | 1 | 0 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$99,438,720 | 81 | 6.74% | $290.44M | |
$5,911,307 | 70 | -1.38% | $309.77M | |
$109,415,500 | 33 | 18.13% | $353.41M | |
$41,446,394 | 27 | 12.91% | $340.18M | |
$56,550,550 | 22 | 50.17% | $270.11M |
PHAT Institutional Investors: Active Positions
| Increased Positions | 98 | +80.33% | 9M | +11.85% |
| Decreased Positions | 50 | -40.98% | 14M | -19.01% |
| New Positions | 38 | New | 2M | New |
| Sold Out Positions | 23 | Sold Out | 8M | Sold Out |
| Total Postitions | 170 | +39.34% | 68M | -7.16% |
PHAT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Frazier Life Sciences Management, L.P. | $55,803.00 | 14.87% | 10.11M | 0 | 0% | 2024-12-31 |
| Medicxi Ventures Management (Jersey) Ltd | $41,204.00 | 10.98% | 7.46M | 0 | 0% | 2024-12-31 |
| Jennison Associates Llc | $38,985.00 | 10.39% | 7.06M | +1M | +20.39% | 2024-12-31 |
| Invesco Ltd. | $20,266.00 | 5.4% | 3.67M | -425,376 | -10.38% | 2024-12-31 |
| Blackrock, Inc. | $19,333.00 | 5.15% | 3.5M | +379,805 | +12.16% | 2024-12-31 |
| Carlyle Group Inc. | $19,302.00 | 5.14% | 3.5M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $15,343.00 | 4.09% | 2.78M | +83,238 | +3.09% | 2024-12-31 |
| Ensign Peak Advisors, Inc | $13,949.00 | 3.72% | 2.53M | -54,334 | -2.1% | 2024-12-31 |
| Checkpoint Capital L.P. | $12,553.00 | 3.34% | 2.27M | +769,850 | +51.18% | 2024-12-31 |
| Nea Management Company, Llc | $10,820.00 | 2.88% | 1.96M | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.